Podcasts about google play store

Time to break out the winter scarves for this weekend's first big away trip to the chilly confines of Saint Paul. FC Cincinnati makes another heralded trek to Minnesota United, hoping to stitch multiple solid performances together. The Orange & Blue have left their history in the past, winning their last two visits to Allianz Field and leaving all memories of their worst loss ever in the snowdrifts. As much as Cincinnati has kept their roster primarily constant in the offseason, the Loons have endured a very turbulent winter with a roster that looks quite different. The promise of superstar James Rodrigues has been tempered with the uncertainty of new head coach Cam Knowles, but the first match at least brought a point back to their home opener. We talk with Dan from The Loony Bin Podcast to analyze the roster shifts and expectations. Can Minnesota alter the trend of Cincinnati taking the wins? Will we hear "Wonderwall" or "Mr. Brightside" after 90 minutes? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Bill Reno is back with a new season of  "Gloves Off" where he takes an unfiltered look at the game with candid conversations w/ former GK's.  This week Bill is joined by Dr. Bill Steffen. The Two discuss his  college career, the mindset of the GK, and how the origins of the ACC Powerhouse Programs.   Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 More Info on All our shows at www.theuniongk.com *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The TKI Crew are back asking the age old question, "Do you have to go a Division 1 school as a goalkeeper to play at the next level? The gang breaks down all the pluses and minuses of focusing solely on D1 opps and why environment matters more than level. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Grundsätzlich sind Doktorspiele ganz normale “Zeig mal, guck mal” -Spiele und wir alle wissen, dass sie irgendwie dazu gehören. Aber wie sollen wir Eltern uns verhalten? Und woran merken wir, wenn es nicht mehr harmlos ist?  In dieser Podcastfolge gibt Nicola einen Überblick, in welchem Alter Doktorspiele normal sind, woran wir erkennen, was unsere Kinder gerade spielen und welche Informationen alle Kinder brauchen.  Mehr bekommst du in unserer App »artgerecht - für Eltern (Selbstfürsorge • Erziehungstipps)« in deinem App Store oder Google Playstore.

In Ephesians 4 & 5, Apostle Paul shows what God's glory looks like in the Church. When the Church is a united body, a genuine community shaped by the lifestyle of following Jesus, a renewed humanity that lives like it, and full of humble people. So, how is that reflected in the posture, the attitude and the practical lifestyle of the members of the Church towards one another?--To hear more messages from The Image Church, subscribe to our podcast or YouTube channel. Also follow us on social media (Facebook and Instagram) or download our Image Church app in the App Store and Google Play Store to learn more about us and stay up to date.

In‑car technology continues to evolve as drivers seek faster, simpler, and more seamless ways to connect their smartphones to their vehicles. Ottocast focuses on wireless CarPlay and Android Auto solutions designed to eliminate the need for cables and reduce the friction that often accompanies daily driving routines. The company develops compact plug‑and‑play devices that convert wired CarPlay systems into wireless experiences, supporting a more convenient and efficient workflow for drivers who rely on navigation, communication, and media throughout the day.The shift toward wireless connectivity reflects a broader trend in automotive technology, where drivers expect their vehicles to integrate smoothly with their digital lives. Many factory‑installed systems still require a physical cable to activate CarPlay or Android Auto, creating inconvenience for users who frequently enter and exit their vehicles. Ottocast addresses this gap by offering a device that plugs directly into the vehicle's USB port and establishes a wireless bridge between the car and the smartphone. Once paired, the system reconnects automatically each time the vehicle starts, eliminating repeated setup steps.Plug‑and‑Play Wireless ConnectivityThe wireless adapter developed by Ottocast uses Bluetooth for initial pairing and Wi‑Fi for ongoing data transmission, enabling low‑latency performance suitable for navigation, calls, and media playback. The device is designed to function as a transparent intermediary, allowing the vehicle to recognize the smartphone as if it were physically connected. This approach supports compatibility across a wide range of vehicles and mobile devices, making the solution accessible to drivers who want wireless functionality without upgrading their entire infotainment system.The convenience of wireless CarPlay and Android Auto is particularly valuable for drivers who rely on frequent stops, such as rideshare and delivery professionals. The ability to enter and exit the vehicle without repeatedly plugging and unplugging a cable reduces wear on ports, saves time, and supports a smoother workflow. The system also benefits everyday drivers who prefer a cleaner cabin environment without visible cables.Expanding the Platform with In‑Car Android SystemsBeyond wireless adapters, Ottocast has developed standalone in‑car Android systems that function as compact computing platforms. These devices plug into the vehicle and provide access to applications from the Google Play Store, enabling navigation, entertainment, and productivity tools directly through the vehicle's display. This approach transforms the infotainment system into a flexible, app‑driven environment that can be customized to the driver's needs.One of the company's recent additions includes a rear‑seat or rear‑facing camera designed to support families with infants or young children. The camera integrates with the in‑car display through picture‑in‑picture or split‑screen modes, allowing drivers to monitor a child safely without turning around. This feature reflects a growing emphasis on safety‑enhancing technologies that reduce distraction while maintaining situational awareness.Global Availability and User‑Focused DesignOttocast's products are available through the company's website and major online retailers, supporting global access to wireless connectivity solutions. The devices are designed for ease of use, requiring no technical expertise or installation services. The company conducts extensive compatibility testing across thousands of vehicle models to ensure reliable performance in diverse markets.The focus on convenience, safety, and user experience positions Ottocast as a contributor to the broader evolution of in‑car technology. As drivers continue to expect seamless integration between their vehicles and their digital ecosystems, solutions that simplify connectivity will remain essential.ConclusionOttocast advances in‑car connectivity through wireless CarPlay and Android Auto adapters, standalone Android systems, and safety‑enhancing camera integrations. By eliminating cables, simplifying setup, and expanding access to app‑driven experiences, the company supports a more convenient and modern driving environment. As automotive technology continues to evolve, wireless solutions like these play a key role in shaping the future of digital mobility.Ottocast devices are available today on Amazon and Ottocast's website.Interview by Scott Ertz of F5 Live: Refreshing Technology.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

In‑car technology continues to evolve as drivers seek faster, simpler, and more seamless ways to connect their smartphones to their vehicles. Ottocast focuses on wireless CarPlay and Android Auto solutions designed to eliminate the need for cables and reduce the friction that often accompanies daily driving routines. The company develops compact plug‑and‑play devices that convert wired CarPlay systems into wireless experiences, supporting a more convenient and efficient workflow for drivers who rely on navigation, communication, and media throughout the day.The shift toward wireless connectivity reflects a broader trend in automotive technology, where drivers expect their vehicles to integrate smoothly with their digital lives. Many factory‑installed systems still require a physical cable to activate CarPlay or Android Auto, creating inconvenience for users who frequently enter and exit their vehicles. Ottocast addresses this gap by offering a device that plugs directly into the vehicle's USB port and establishes a wireless bridge between the car and the smartphone. Once paired, the system reconnects automatically each time the vehicle starts, eliminating repeated setup steps.Plug‑and‑Play Wireless ConnectivityThe wireless adapter developed by Ottocast uses Bluetooth for initial pairing and Wi‑Fi for ongoing data transmission, enabling low‑latency performance suitable for navigation, calls, and media playback. The device is designed to function as a transparent intermediary, allowing the vehicle to recognize the smartphone as if it were physically connected. This approach supports compatibility across a wide range of vehicles and mobile devices, making the solution accessible to drivers who want wireless functionality without upgrading their entire infotainment system.The convenience of wireless CarPlay and Android Auto is particularly valuable for drivers who rely on frequent stops, such as rideshare and delivery professionals. The ability to enter and exit the vehicle without repeatedly plugging and unplugging a cable reduces wear on ports, saves time, and supports a smoother workflow. The system also benefits everyday drivers who prefer a cleaner cabin environment without visible cables.Expanding the Platform with In‑Car Android SystemsBeyond wireless adapters, Ottocast has developed standalone in‑car Android systems that function as compact computing platforms. These devices plug into the vehicle and provide access to applications from the Google Play Store, enabling navigation, entertainment, and productivity tools directly through the vehicle's display. This approach transforms the infotainment system into a flexible, app‑driven environment that can be customized to the driver's needs.One of the company's recent additions includes a rear‑seat or rear‑facing camera designed to support families with infants or young children. The camera integrates with the in‑car display through picture‑in‑picture or split‑screen modes, allowing drivers to monitor a child safely without turning around. This feature reflects a growing emphasis on safety‑enhancing technologies that reduce distraction while maintaining situational awareness.Global Availability and User‑Focused DesignOttocast's products are available through the company's website and major online retailers, supporting global access to wireless connectivity solutions. The devices are designed for ease of use, requiring no technical expertise or installation services. The company conducts extensive compatibility testing across thousands of vehicle models to ensure reliable performance in diverse markets.The focus on convenience, safety, and user experience positions Ottocast as a contributor to the broader evolution of in‑car technology. As drivers continue to expect seamless integration between their vehicles and their digital ecosystems, solutions that simplify connectivity will remain essential.ConclusionOttocast advances in‑car connectivity through wireless CarPlay and Android Auto adapters, standalone Android systems, and safety‑enhancing camera integrations. By eliminating cables, simplifying setup, and expanding access to app‑driven experiences, the company supports a more convenient and modern driving environment. As automotive technology continues to evolve, wireless solutions like these play a key role in shaping the future of digital mobility.Ottocast devices are available today on Amazon and Ottocast's website.Interview by Scott Ertz of F5 Live: Refreshing Technology.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

With the midweek win done and dusted, we can finally focus on the meat and potatoes of the MLS regular season! Just two months away from competition feels like a hunger strike, especially after watching That Team From Florida enjoy all the fine dining last December. FC Cincinnati heads into Season 5 under Pat Noonan with some big statements to make, but let's not forget that this weekend's opponent experienced bigger disappointment after promises of gold. Atlanta United brought the band back together by rehiring their best conductor, Tata Martino, to helm the sidelines. What can we expect out of the "5 Stripes" with a similar roster and a more familiar head coach? We've brought in an old friend to the show, Tyler Pilgrim from Scarves & Spikes, to set the table for Saturday. Can Atlanta bring back the golden days of the 2010s and get back on the medal stand again? What will the Starting XI look like under Martino's guidance? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

This week, we're revisiting an episode where Marianna sat down with John Faragon to talk about post-exposure prophylaxis in pocket or PIP. Listen in to learn all about what it is, who it's for, and how it can help prevent HIV for more people.-- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

In Episode 56 Landon urges us to slow down a bit, to relax. One of the ways in which we accomplish this is to Embrace Life's Undeniables. This is the 4th Key to living fully...excerpted from "The Significant Seven", a 7-part addition to the Heartbeat App. You can get the entire course, including thought provoking insights from Landon and an accompanying exploration workbook, now included in the Heartbeat App. The App is free, and can be downloaded from the Apple App Store or the Google Play Store.

The TKI Crew keeps it rolling with a "Brave" Pod :P. That's right, today's topic is what it means to be a brave goalkeeper. The crew breaks it down from a micro and macro standpoint.  Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I18 GK Podcast is back this month w/ Sac Republic's Kris Hall! The crew chat overseas badges, the upcoming USSF course, and how to balance your independent academy w/ your Pro Club's commitments. Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code: Union GK members can save an additional 10% with code: UGK23. Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment. Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Want to increase your organic downloads without spending money on ads? In this video, I break down our proven app store optimization (ASO) framework for 2026. Whether you are an indie developer or managing a big brand, these strategies will help you rank higher on both the Apple App Store and Google Play Store.We cover the exact steps we use at App Masters to help clients find success, from keyword research to conversion rate optimization.In this ASO tutorial, you will learn:✅ The most important ASO ranking factors in 2026✅ How to find low-competition keywords that still drive revenue✅ The do's and dont's of selecting keywords✅ Some Real Case Studies:- $1,600 in revenue in the first 22 days from organic search- $3,000/month purely from long-tail ASO strategy- 90+ #1 keyword rankings using low-traffic terms

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss their favorite album releases of the year 1996! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

For many Christians the biblical idea of being justified by faith is all that matters and Christian behavior is often equal to religion and unnecessary regulations. Many want Jesus as a savior, but not as a lifestyle. The Church isn't just saved from sin, the Church is meant to display God, through a lifestyle modeled and taught by Jesus.--To hear more messages from The Image Church, subscribe to our podcast or YouTube channel. Also follow us on social media (Facebook and Instagram) or download our Image Church app in the App Store and Google Play Store to learn more about us and stay up to date.

In dieser Episode sprechen wir mit Alexander Metzler über einen gesunden Lifestyle ohne Extremismus. Kein Selbstoptimierungs-Wahn, kein Dogma – sondern echte Balance.Wir reden darüber, wie Biohacking im Alltag wirklich funktioniert, warum Eisbaden und Atemtechniken mehr sind als nur ein Trend und wieso Resilienz nicht durch Verzicht, sondern durch Bewusstsein entsteht.Außerdem geht es um körperliche Gesundheit, Spiritualität, Medienkonsum, Schlafqualität, Ernährung und die Frage: Wie bleibt man stabil in einer Welt voller Reize – ohne zum Gesundheits-Roboter zu werden?PS: Tonka genießt aktuell ihren Mutterschutz und ist deshalb in dieser Folge nicht zu hören. ❤️Hier geht es zu Alexanders Website und Instagram:https://alexander-metzler.com/https://www.instagram.com/_alexandermetzler/Support the show____________________________________________ Die Folge hat dir Lust auf mehr gegeben? Dann abonniere unseren Podcast und helfe uns mit einer 5-Sterne Bewertung auf Spotify & iTunes! Willst du unsern Podcast gerne im Videoformat sehen? Dann schaue dir alle Folgen in unserer App "MindClub" an!App Store: https://apps.apple.com/np/app/mind-club/id1643729107 Google Play Store: https://play.google.com/store/apps/details?id=tv.uscreen.mindclubOder auf Youtube: https://www.youtube.com/channel/UCFg1XNY1KVcb1WQWbcKCmOQ/featuredWillst du selbst mit dem Meditieren beginnen? Im Mindclub findest du eine Vielzahl von geführten Meditationen in Audio- und Videoform, sowie Live-Sessions: https://www.mindclubapp.com/Instagram: https://www.instagram.com/mindfulife.de/Facebook: ...

At ITEXPO / MSP EXPO in Fort Lauderdale, Doug Green, Publisher of Technology Reseller News, spoke with Jon Brinton, Chief Revenue Officer at Crexendo, about the company's latest announcement: the launch of the Crexendo Marketplace. Crexendo is also a member of the Cloud Communications Alliance (CCA). Crexendo, a unified communications service provider, merged with NetSapiens five years ago, bringing together a robust UCaaS platform now powering approximately 240 service providers globally. That ecosystem supports nearly 7.5 million users—a number that has grown more than fourfold since the acquisition. The new Crexendo Marketplace builds on that momentum by delivering a centralized, frictionless application store for certified integrations and third-party solutions. “What we've now released is a Crexendo Marketplace,” Brinton explained. “If you think about it like the Google Play Store or the Apple Store, it's an application store that somebody can go to download, activate or integrate with applications that are certified for our platform.” Through one-touch provisioning, service providers can enable integrations such as mobile dialer support, analytics, Microsoft Teams connectivity, and Crexendo's AI-powered receptionist and orchestrator, Cairo—all without complex implementation paths. The Marketplace reinforces Crexendo's sessions-not-seats licensing model, which allows MSPs and service providers to own their customer relationships while building equity in their businesses. Brinton noted that AI-driven add-on applications are driving significant incremental revenue, often far exceeding traditional per-user UCaaS pricing. “Some of these AI applications… may be worth four to five to ten times that in monthly revenue to our partners,” he said, underscoring the opportunity for higher-margin growth. As innovation accelerates across the cloud communications landscape, Crexendo continues to invest heavily in platform development and ecosystem expansion. With its annual NetSapiens user group meeting scheduled for Austin later this year, the company remains focused on empowering partners with tools, integrations, and community support to compete—and win—in an evolving market. Visit https://www.crexendo.com/

One week until meaningful soccer and the launch of a promising FC Cincinnati season! We enter Year 11 the same way as last season, with the Orange & Blue leaving the country for CONCACAF Champions Cup coverage. Soon enough, the MLS season also starts with designated players Evander, Miles Robinson, and Kevin Denkey leading a talented roster. But what are we really looking at? How promising and hopeful are we that this roster can use consistency and build from last season's hard work? We ask the FC Cincinnati radio broadcast team, Tommy G. and Kevin McCloskey, what they think about this roster and the long road ahead. (And perhaps a bit about the big tournament this summer!) Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Good evening Vital family and friends. We are so blessed to have you join with us this evening as we begin our series on “Working At God's Altar”, following the book of the same title written by Don Nordin. If you are joining us on any of our social media platforms, we invite you to download our Vital Church app from the Apple App Store or Google Play Store so you can access the work sheet to follow along with the lesson.New to Vital Church? Connect with us here! https://myvital.church/new-here•Need Prayer? We would love to pray for you! https://myvital.church/prayer-request•Made a decision for Christ? https://myvital.church/made-a-decision•Looking to give? https://myvital.church/give 

The TKI Crew returns for Winter 2026! On Today's episode, Jill ,Tori and Kira discuss how college goalkeepers can transition into coaching. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss the singles of the year 1996! And stay tuned for Side 2: The Albums next week! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

FC Cincinnati has officially played ten years of soccer for the Queen City. Fans have experienced a decade of the highest highs and lowest lows, and we here at Cincinnati Soccer Talk have been there every minute along the way. We've held wooden spoons and supporter shields with the fans. We've held the microphones in front of the players and coaches. Ever since the hosts met for their first podcast in February of 2016, CST has worked to paint the picture of Cincinnati as a soccer city. (In some cases, that paint involved actual body paint!) To open the year's first Jersey Swap podcast, we've brought in some of our alumni—Nick Seuberling, Bryan Weigel, and Bill Wolf—to talk about CST's origins and best moments. Additionally, we ask them about how confident we feel about the 2026 season. And maybe we wrap things up with a quiz to see how well the triad remember that first season! Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Every other week I'm republishing one of my most popular or impactful episodes from my backlog of over 450 episodes. This week I'm highlighting Episode 410, which is all about post-op pediatric airway emergencies.  You don't want to miss this one! ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠Episode 140⁠ - Listen to episode 140 for an overview of pediatric respiratory distress. ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Study Sesh⁠ - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. NCLEX Study Plan - Not sure how to plan your NCLEX studying or which topics to focus on? Grab this free guide which details strategies based on how much time you have to prepare.

This week, Marianna sits down with Chris Bositis and Cara McAnaney from the National Clinician Consultation Center (NCCC) to talk all about lower-barrier substance use and HIV prevention and treatment. Tune in to learn how direct-to-inject ties into that and why it matters for you as an HIV care provider. -- Resources: Waters RC, Hoog J, Bell C, Toland P, Valley J, Hurtado L, Kallsen MA, Johnson T, Gerard A, Fockele CE, Klein JW. Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting. JAMA Netw Open. 2025 Aug 1;8(8):e2527016. doi: 10.1001/jamanetworkopen.2025.27016. PMID: 40815514; PMCID: PMC12357186.Rosenwohl-Mack S, Suen LW, Logan AA, Peterson D, Snyder HR. Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series. Subst Use Addctn J. 2025 Oct;46(4):1064-1069. doi: 10.1177/29767342251330412. Epub 2025 Apr 4. PMID: 40183345; PMCID: PMC12353995.D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702. PMID: 38976265; PMCID: PMC11231806. Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

The TKI Crew returns for Winter 2026! On Today's episode, Jill & Tori are joined by a special guest (possibly a new cast member? :P ) Kira Ketelhut to discuss what are 3 main takeaways from offseason Pro GK training week that young goalkeepers can learn from. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

The fellas are back and in grand fashion covering everything with the week between the NFL in mind: coaching hires, big moves, previewing the offseason and where do the losers of the conference championship go from here?

In this episode of The EV Musings Podcast, Gary discusses the impact of cold weather on electric vehicles, focusing on battery performance, heating solutions, and practical tips for driving in winter conditions.He explains how cold temperatures affect battery chemistry, leading to reduced range, and offers insights into efficient heating methods, including the use of heat pumps and heated accessories.The episode concludes with essential tips for maximising EV performance in cold weather.The EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence.Links in the show notes:Range test: How far can electric cars go in winter?Episode produced by Arran Sheppard at Urban Podcasts: https://www.urbanpodcasts.co.uk(C) 2019-2026 Gary ComerfordSupport me: Patreon Link: http://www.patreon.com/evmusingsKo-fi Link: http://www.ko-fi.com/evmusingsThe Books:'So, you've gone electric?' on Amazon : https://www.amazon.co.uk/dp/B07Q5JVF1X'So, you've gone renewable?' on Amazon : https://amzn.to/3LXvIckSocial Media:EVMusings: Twitter https://twitter.com/MusingsEvInstagram: @EVmusingsOctopus Energy referral code (Click this link to get started) https://share.octopus.energy/neat-star-460Upgrade to smarter EV driving with a free week's trial of Zapmap Premium, find out more here https://evmusings.com/zapmap-premiumMentioned in this episode:ZapmapThe EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence. Zapmap is free to download and use, with subscription plans for enhanced features such as using Zapmap in-car on CarPlay or Android Auto, and discounted charging across thousands of charge points. Download the app from the Apple App Store or Google Play Store or find out more at www.zapmap.com.Zapmap EV GuideGlobal Women in EV DayThis episode is supported by Global Women in EV Day, an international movement founded by Gill Nowell to celebrate and accelerate the women driving the EV transition. Launching globally on 10 February 2026, the campaign brings the sector together around visibility, equity and action. More info: gillnowell@hostedbygill.co.ukGlobal Women in EV Day

We've all made New Year's resolutions before, right? Right? Okay, not all of us. But at least 3 out of 4 Geek Salad members at least remember making a resolution at some point in the past. So to chat about some of those and just kick off the new year in general, they give you episode 263: Resolve to Resolve My New Year's Resolutions. Join Andy, Mike, Joe, and Katherine as they talk about New Years past, present, or yet to come. How many resolutions have they made and kept versus made and completely forgot about a week later? And what do they have planned for the upcoming 12 months? Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.

Bill Reno is back with a new season of  "Gloves Off" where he takes an unfiltered look at the game with candid conversations w/ former GK's.  This week Bill is joined by Dynasty GK Founder & Former USWNT WC Winning GK Tracy Noonan. The Two discuss her college career, the state of USWNT, and how she's paying it forward to the next generation with Dynasty GK.   Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 More Info on All our shows at www.theuniongk.com *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

When overhead is high, you buy cheaper supplies. But there's a better way! In this episode, Kirk Behrendt brings back Ariel Siegel, one of ACT's amazing coaches, to continue the series on overhead and break down supplies percentage. She shares why your numbers may be high, how that impacts your practice, and what you can do about it. For the treatment plan to reduce waste and overspending on supplies, listen to Episode 1000 of The Best Practices Show!Learn More About Ariel:Send Ariel an email: ariel@actdental.com Follow Ariel on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:...

We had a kwentuhan with G Delivers last Philippine Startup Week 2025!G Delivers is your All-in-One Delivery & Transport App! Get food, pharmacy items, groceries, shop essentials, parcels, e-commerce orders, all in one app. Download now on Google Play Store! About to launch in App Store!This episode is recorded live at the Philippine Innovation Hub in Marikina City.In this episode:00:00 Introduction02:33 Ano ang G Delivers?How can listeners find more information?G DELIVERSWebsite: https://g-delivers.comFacebook: https://facebook.com/gdeliversphilippinesPHILIPPINE STARTUP WEEKWebsite: https://phstartupweek.comFacebook: https://facebook.com/PhilippineStartupWeekTHIS EPISODE IS CO-PRODUCED BY:Kredit Hero: ⁠⁠⁠https://kredithero.com/⁠⁠⁠Yspaces: ⁠⁠⁠https://knowyourspaceph.com⁠⁠⁠Twala: ⁠⁠⁠https://twala.io⁠⁠⁠Symph: ⁠⁠⁠https://symph.co⁠⁠⁠Secuna: ⁠⁠⁠https://secuna.io⁠⁠⁠SkoolTek by Edfolio: ⁠⁠⁠https://skooltek.co⁠⁠⁠MaroonStudios: ⁠⁠⁠https://maroonstudios.com⁠⁠⁠CompareLoans: ⁠⁠⁠http://compareloans.ph⁠⁠⁠CHECK OUT OUR PARTNERS:Ask Lex PH Academy: ⁠⁠⁠https://asklexph.com⁠⁠⁠ (5% discount on e-learning courses! Code: ALPHAXSUP)ArkoTech: ⁠⁠⁠https://www.arkotechspacesolutions.com/⁠⁠⁠DVCode Technologies Inc: ⁠⁠⁠https://dvcode.tech⁠⁠⁠NutriCoach: ⁠⁠⁠https://nutricoach.com⁠⁠⁠Argum AI: ⁠⁠⁠http://argum.ai⁠⁠⁠PIXEL by Eplayment: ⁠⁠⁠https://pixel.eplayment.co/auth/sign-up?r=PIXELXSUP1⁠⁠⁠ (Sign up using Code: PIXELXSUP1)School of Profits: ⁠⁠⁠https://schoolofprofits.academy⁠⁠⁠Founders Launchpad: ⁠⁠⁠https://founderslaunchpad.vc⁠⁠⁠Hier Business Solutions: ⁠⁠⁠https://hierpayroll.com⁠⁠⁠Agile Data Solutions (Hustle PH): ⁠⁠⁠https://agiledatasolutions.tech⁠⁠⁠Smile Checks: ⁠⁠⁠https://getsmilechecks.com⁠⁠⁠CloudCFO: ⁠⁠⁠https://cloudcfo.ph⁠⁠⁠ (Free financial assessment, process onboarding, and 6-month QuickBooks subscription! Mention: Start Up Podcast PH)Cloverly: ⁠⁠⁠https://cloverly.tech⁠⁠⁠BuddyBetes: ⁠⁠⁠https://buddybetes.com⁠⁠⁠HKB Digital Services: ⁠⁠⁠https://contakt-ph.com⁠⁠⁠ (10% discount on RFID Business Cards! Code: CONTAKTXSUP)Hyperstacks: ⁠⁠⁠https://hyperstacksinc.com⁠⁠⁠OneCFO: ⁠⁠⁠https://onecfoph.co⁠⁠⁠ (10% discount on CFO services! Code: ONECFOXSUP)Wunderbrand: ⁠⁠⁠https://wunderbrand.com⁠⁠⁠Uplift Code Camp: ⁠⁠⁠https://upliftcodecamp.com⁠⁠⁠ (5% discount on bootcamps and courses! Code: UPLIFTSTARTUPPH)START UP PODCAST PHYouTube: ⁠⁠⁠https://youtube.com/startuppodcastph⁠⁠⁠Spotify: ⁠⁠⁠https://open.spotify.com/show/6BObuPvMfoZzdlJeb1XXVa⁠⁠⁠Apple Podcasts: ⁠⁠⁠https://podcasts.apple.com/us/podcast/start-up-podcast/id1576462394⁠⁠⁠Facebook: ⁠⁠⁠https://facebook.com/startuppodcastph⁠⁠⁠Patreon: ⁠⁠⁠https://patreon.com/StartUpPodcastPH⁠⁠⁠PIXEL: ⁠⁠⁠https://pixel.eplayment.co/dl/startuppodcastph⁠⁠⁠Website: ⁠⁠⁠https://phstartup.online⁠⁠⁠This episode is edited by the team at: ⁠⁠⁠https://tasharivera.com⁠⁠

Success isn't just about the medals. In this episode, Kirk Behrendt brings back Dr. Amanda Seay, president of the AACD, and Dr. Zach Sisler, board chair of the AACD, to share their journeys and lessons of the accreditation process and the importance of investing in yourself for your future. To learn what success could look like for you, listen to Episode 999 of The Best Practices Show!Learn More About Dr. Seay & Dr. Sisler:Join Dr. Seay on Facebook: https://www.facebook.com/DrAmandaSeayFollow Dr. Seay on Instagram: https://www.instagram.com/dramandaseayJoin Dr. Sisler on Facebook: https://www.facebook.com/SmilesBySislerFollow Dr. Sisler on Instagram: https://www.instagram.com/dr_zachsislerRegister for the AACD Scientific Session (April 16-18, 2026): https://www.aacdconference.com/event/1a1b9fe4-2097-4006-b107-822d4da3654b/main-menuMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store:

This week, Marianna sits down with John Faragon to talk about managing missed doses of common injectable medications for treating HIV. Learn all about the different medication options and paths to take as an HIV care provider when doses have been missed. --Long-Acting Injectable PrEP: https://nastad.org/sites/default/files/2023-04/LAI-FAQ-Formatted-Updated4.17.23.pdfLenacapavir as HIV PrEP: https://www.cdc.gov/mmwr/volumes/74/wr/pdfs/mm7435-H.pdf--Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Your expenses go up year over year — and so should your fees! In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to help you think better about your fees and provide tips for when and how to raise them. To learn how to start owning your value and charging what you're worth, listen to Episode 998 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

I18 GK Podcast is proud to present a very special conversation with US Soccer's Head of Goalkeeping Jack Robinson.  The crew chat how to develop a nat gk program, how to build a goalkeeper pool in a country of such scale, and how US Soccer is paving the way for cultural gk exchange from grassroots all the way to the professional game!  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT alone, ADT and an ARPI, ADT and docetaxel, and ADT, an ARPI, and docetaxel whose disease has progressed to mCRPC and the evidence that underpins these changes. Dr. Taplin highlights the updated algorithms within the guideline and the living format which will provide rapid, up-to-date, evidence-based information for clinicians and patients. Read the full living guideline update, "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." at www.asco.org/genitourinary-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02693 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Mary-Ellen Taplin from Dana-Farber Cancer Institute, lead author on "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." Thank you for being here today, Dr. Taplin. Dr. Mary-Ellen Taplin: Thank you, Brittany. It is a pleasure. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplin who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To dive into the content here and what we are here today to talk about, this living clinical practice guideline for systemic therapy for patients with metastatic castration-resistant prostate cancer is updated on an ongoing basis. Dr. Taplin, what prompted this latest update to the recommendations? Dr. Mary-Ellen Taplin: Thank you, Brittany. Several things prompted the latest update. There have been several phase III trials that have been practice-changing that have resulted in the last several years that needed to be added to the guidelines to inform clinicians of comprehensive treatment options. Brittany Harvey: Great, and it is great to have this updated guideline for readers. I would like to review the changes to the recommendations in this latest iteration across the patient populations that are outlined in the guideline. So, starting with: What are the updated recommendations for patients previously treated with androgen deprivation therapy alone whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: A nice feature of this guideline is that in addition to the tables, which provide detailed options, is at the end of the guidelines, our readers will find very clear algorithms that describe past treatment scenarios that patients could have had and then outline their treatment options. So it is very clear. Our clinicians will love these algorithms. And one of the changes for the disease state that you mentioned, which is the least treated castration-resistant state of prostate cancer which is previously treated with ADT alone, is that we recommend testing for mutations in the HRR, homologous recombination repair, genes. And the ones that are specifically known and applicable to prostate cancer are the BRCA genes. So there is clear recommendation of testing to remind us, as treating physicians, that now is the time, if it hasn't been done before, to institute both germline and somatic testing. And somatic testing, if it can be done on tissue, is preferable, but if not, the liquid biopsy approaches, the ctDNA approaches, have now advanced to the point that most patients with metastatic prostate cancer will be able to successfully have testing on the liquid biopsies. So that is number one, testing. And then the new treatment options include, if a patient does have an HRR gene alteration, and maybe about 20-25 percent of patients will be in that category, the combinations of an androgen pathway inhibitor and a PARP inhibitor are now treatment options. So for instance, talazoparib and enzalutamide; olaparib and abiraterone; or niraparib and abiraterone are some of the newer treatment options if the patient is HRR-positive. So, Brittany, in regard to patients treated with ADT alone, another new treatment option is the combination of radium-223 with enzalutamide. This is data based on the PEACE-3 trial which did show both an rPFS and OS benefit. For the patient who is HRR-negative and has previously not had an ARPI, just ADT alone, the combination of radium and enzalutamide is a new recommendation added to the algorithm. Brittany Harvey: Great. Thank you for reviewing those options for that patient population. And as you mentioned, I think those algorithms are very helpful as figures in the document. They are clear and can be used as at-a-glance tools for clinicians in their busy clinics. So then the next patient population that the guideline addresses: What is new for patients previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Right, so there are several new treatment options. So one is lutetium-PSMA-617, the trade name of which is Pluvicto. So that has now been FDA approved to use after progression on an AR pathway inhibitor and prior to the use of docetaxel chemotherapy. Brittany Harvey: Thank you for reviewing that new option for patients treated with androgen deprivation therapy and an ARPI whose disease has progressed. So then moving into the next set of recommendations, what does the panel now recommend for patients previously treated with androgen deprivation therapy and docetaxel whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: The next group of patients is those treated with ADT and docetaxel but haven't had an AR pathway inhibitor. Treatment options, again the HRR testing is important. So all patients with metastatic castration-resistant prostate cancer should be considered for both germline and somatic testing. I will repeat that. And if they are BRCA mutation positive, then the option of talazoparib and enzalutamide; olaparib and abiraterone; and niraparib and abiraterone.  So the AR pathway inhibitors plus the PARPs. There are three choices, so that can be somewhat complicated to think through, but most practitioners will get familiar with one of those combinations and be their go-to. So those are for BRCA-positive or HRR-positive. The talazoparib/enzalutamide trial also included non-BRCA HRR-positive gene mutations. And if they are HRR-negative, the option that we discussed above of radium and enzalutamide is new to the guideline. Brittany Harvey: Great. And then the last category of patients that is addressed in this update: What has changed for patients previously treated with androgen deprivation therapy, an androgen receptor pathway inhibitor, and docetaxel whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Well, in this space, patients who are heavily pretreated with ADT and ARPI, one or even two, and chemotherapy, generally with docetaxel, the recommendations are not new within the last year or two. And they include Pluvicto; a PARP inhibitor if HRR-positive and they have not had one; second-line chemotherapy such as cabazitaxel. And if they are a very rare group and they have been sequenced and they are MSI-high, then considering a PD-1 inhibitor such as pembrolizumab can be considered. I will note that this is a very small percentage of mCRPC patients, probably in the order of 5 percent or less. Brittany Harvey: Understood. And I appreciate you reviewing the recommendations across all of these patient populations. It sounds like some of the key points is that HRR testing is very important for this patient population, and that the algorithms and the tables in the manuscript provide the full list of options that clinicians and patients can refer to. Dr. Mary-Ellen Taplin: Those are the highlights. And I will note in the tables, all the sections have "Special Considerations" sections because patients never fall into the black and white of one category. And those practical information or special situations sections of each of the recommendations can also help clinicians think about the individual patient in front of them and how they might choose one therapy over another since there are generally choices in all of these treatment situations. Brittany Harvey: Absolutely. That information for the individualized patient-clinician decision-making is really key when, as you said, there is a list of options to choose from. So in your view, what should clinicians know as they implement this living guideline update, and how do these changes impact patients? Dr. Mary-Ellen Taplin: I am so excited about this living document. ASCO has invested to developing the software to, in real time and iteratively, assess the new data that is published in prostate cancer and other diseases. So now we don't have to wait many years for the next guideline to come out. The guidelines will be updated every six months in prostate cancer based on this automatic search of the literature and a standing panel of both academic and community experts in prostate cancer treatment. So we no longer have to wait. That is what makes this guideline stand out to other guidelines. And in the digestible format that we have made, a clinician can seek out the table and read some details, seek out practical information for the recommendations, or they can just go right to the clear figure algorithm and take a quick snapshot. "Yep, I need to do HR testing. Done. Oh, okay. HR-positive or negative, these are my options," and then think about the individual patient in front of them when there is more than one option. For instance, a patient with cardiovascular history, abiraterone might not be a good choice for them. Or a patient with neuropathy, docetaxel might not be a good choice for them. But, within this guideline, it really will be up to date and focused on the busy clinician and knowing what the options are for their patient. Brittany Harvey: Definitely. This new era of living guidelines is very exciting and can provide even more up-to-date, evidence-based recommendations to really support clinicians and patients with metastatic castration-resistant prostate cancer. So in that vein, finally, what is the panel examining, and what are you excited for for new data coming out for future updates to this living guideline? Dr. Mary-Ellen Taplin: The future updates will depend on the results of phase III clinical trials. You know, there are many phase III trials ongoing in advanced prostate cancer, some of which include targeted therapy, which has been long awaited in prostate cancer. So such compounds as antibody-drug conjugates that are targeting certain proteins in prostate cancer cells, such as STEAP1, KLK2, B7-H3. So I think we are entering a new era in prostate cancer where we will be targeting cells and delivering drugs and applying them to prostate cancer if the trials are positive. So I think with AI and a large investment in prostate cancer clinical drug development, I think the treatment options for our patients will be rapidly evolving in a manner not previously seen. So the guidelines need to follow along with these developments. Brittany Harvey: Definitely. It sounds like an exciting time for research in metastatic castration-resistant prostate cancer. And we will await the result of those phase III trials to inform this guideline and lead to future updates. So I want to thank you so much for your work to rapidly and continuously update these guidelines and for your time today, Dr. Taplin. Dr. Mary-Ellen Taplin: Oh, it was my pleasure. ASCO has been a leader in this area, and as a practicing clinician, we are thankful for the investment and guidance that ASCO gives us. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Your accountant says your practice is profitable. So, why doesn't it feel like it? In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down the cash flow gap, what it is, and how not understanding it affects your practice. To learn how to close your cash flow gap so you can grow your practice, listen to Episode 997 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Every year, you set goals to become healthier. But every year, you fall off the wagon! In this episode, Kirk Behrendt brings back Dr. Uche Odiatu, one of ACT's favorite health and wellness gurus, to share three steps to stay on course to improve your health and life. To learn how to stop overthinking and just start doing, listen to Episode 996 of The Best Practices Show!Learn More About Dr. Odiatu:Send Dr. Odiatu an email: odiatudmd@gmail.comFollow Dr. Odiatu on Instagram: https://www.instagram.com/fitspeakersLearn more on Dr. Odiatu's website: http://www.druche.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Things happen that you don't plan for — and you want to be prepared! In this episode, Kirk Behrendt brings back Paul Sletten, founder of The Sletten Group, to share how to plan for the unplanned by creating a crisis coverage group to protect you and your practice. To learn how to plan smarter and have peace of mind, listen to Episode 995 of The Best Practices Show!Learn More About Paul:Give Paul a call: (303) 699-0990Send Paul an email: paul@lifetransitions.com Learn more about The Sletten Group: https://theslettengroup.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Happy New Year! I18 GK Podcast is back for 2026!  99WC Winner Saskia Webber and Comedian Michael Magid are joined by The TKI Podcast and Gloves OFF Crew continue their debate and bracket breakdown of the Final 4 Schools and crown our GKU!   64 Team Bracket avail online .  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Is your practice creating wealth, or is it just keeping you “busy”? In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down production, why it's important to understand, and how to start improving your numbers. To learn how to be more profitable so you have a better practice and better life, listen to Episode 994 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Avoiding conflict is like ignoring a cavity — it will eventually become a crisis! In this episode, Kirk Behrendt brings in Michelle Wakeman, one of ACT's amazing coaches, to share the right way to address conflict so your team and practice can function at their best. To learn how to proactively manage conflict as a leader, listen to Episode 993 of The Best Practices Show!Learn More About Michelle:Send Michelle an email: michelle@actdental.com Follow Michelle on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email to learn more about ACT: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

Are you struggling to figure out shared network agreements? In this episode, Kirk Behrendt brings back Sandi Hudson, founder of Unlock the PPO, to help you navigate the complex world of PPOs with her expert advice. To learn everything you need to know about shared network agreements for the new year, listen to Episode 992 of The Best Practices Show!Learn More About Sandi:Join Sandi on Facebook: https://www.facebook.com/UnlockThePPOFollow Sandi on Instagram: https://www.instagram.com/unlocktheppoLearn more about Unlock the PPO: https://unlocktheppo.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:

On Dec. 10, it was announced that Google would pay nearly $700 million in settlements to people who paid to download apps from the Google Play Store.The announcement came in the form of a statement from multiple state attorneys general, who were collectively suing Google for anti-competitive practices.Google decided to settle this lawsuit—along with several other concessions—and, in so doing, will pay $700 million, the bulk of which will go to the actual users.Let's go through the details of the case: what Google was accused of doing, how the settlement money will be disbursed, and how you can know if you qualify.